Drug intelligence / Profile preview

KT07

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KT07 is an investigational small molecule drug being developed in oral capsule form for the alleviation of fever and other symptoms associated with acute uncomplicated influenza, including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats. Its mechanism of action is currently unknown. Clinical development has included phase 1 pharmacokinetics studies in healthy adults to assess safety and tolerability[1][2][3], as well as a phase 2 randomized controlled trial evaluating efficacy in subjects with confirmed acute uncomplicated influenza[5]. The developer is Yiling.

Beyond the preview

Go deeper on KT07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT07.

Explore the full profile